Furthermore, PBRM1 mutations are significantly associated with response to anti-PD1 therapy, progression-free survival, and OS in patients with advanced ccRCC, but the predictive value is still unclear and needs to be further investigated in future larger randomized trials (Braun et al., 2019; Carril-Ajuria et al., 2019). The gene discussed is PBRM1; the disease is nonpapillary renal cell carcinoma.